{
    "clinical_study": {
        "@rank": "1493", 
        "arm_group": [
            {
                "arm_group_label": "Placebo + pemetrexed/cisplatin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo controlled arm"
            }, 
            {
                "arm_group_label": "Nintedanib + pemetrexed/cisplastin", 
                "arm_group_type": "Experimental", 
                "description": "Experimental arm"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an exploratory study designed to evaluate the safety and efficacy of nintedanib\n      (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120)\n      versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients\n      with unresectable malignant pleural mesothelioma."
        }, 
        "brief_title": "Nintedanib (BIBF 1120) in Mesothelioma", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Mesothelioma", 
        "condition_browse": {
            "mesh_term": "Mesothelioma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Histologically confirmed malignant pleural mesothelioma (MPM) (subtype: epithelioid\n             or biphasic)\n\n          -  Life expectancy of at least 3 months in the opinion of the investigator\n\n          -  Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\n\n          -  Measurable disease according to modified RECIST (Response Evaluation Criteria In\n             Solid Tumours) criteria\n\n        Exclusion criteria:\n\n          -  Previous systemic chemotherapy for MPM\n\n          -  Prior treatment with nintedanib or any other VEGFR (Vascular Endothelial Growth\n             Factor Receptor) inhibitor\n\n          -  Patients with sarcomatoid subtype MPM\n\n          -  Patients with symptomatic neuropathy\n\n          -  Radiotherapy (except extremities) within 3 months prior to baseline imaging\n\n          -  Active brain metastases (e.g. stable for < 4 weeks)\n\n          -  Radiographic evidence of cavitary or necrotic tumours or local invasion of major\n             blood vessels by MPM\n\n          -  Significant cardiovascular diseases\n\n          -  Inadequate hematologic, renal, or hepatic function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "86", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907100", 
            "org_study_id": "1199.93", 
            "secondary_id": "2012-005201-48"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nintedanib + pemetrexed/cisplastin", 
                "description": "triple kinase inhibitor", 
                "intervention_name": "Nintedanib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo + pemetrexed/cisplatin", 
                "description": "backbone chemo", 
                "intervention_name": "Pemetrexed", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Nintedanib + pemetrexed/cisplastin", 
                "description": "backbone chemo", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo + pemetrexed/cisplatin", 
                "description": "backbone chemo", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Nintedanib + pemetrexed/cisplastin", 
                "description": "backbone chemo", 
                "intervention_name": "Pemetrexed", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo + pemetrexed/cisplatin", 
                "description": "Nitedanib matching placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Cisplatin"
            ]
        }, 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "1199.93.10003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "1199.93.10002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "1199.93.10001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "1199.93.10005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Leonards", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }, 
                    "name": "1199.93.61003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chermside", 
                        "country": "Australia", 
                        "state": "Queensland"
                    }, 
                    "name": "1199.93.61002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "1199.93.61004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nedlands", 
                        "country": "Australia", 
                        "state": "Western Australia"
                    }, 
                    "name": "1199.93.61001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "1199.93.11001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "1199.93.11002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f8benahvn \u00d8", 
                        "country": "Denmark"
                    }, 
                    "name": "1199.93.45001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille Cedex 20", 
                        "country": "France"
                    }, 
                    "name": "1199.93.33002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse Cedex 9", 
                        "country": "France"
                    }, 
                    "name": "1199.93.33003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif Cedex", 
                        "country": "France"
                    }, 
                    "name": "1199.93.33001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany"
                    }, 
                    "name": "1199.93.49003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gro\u00dfhansdorf", 
                        "country": "Germany"
                    }, 
                    "name": "1199.93.49001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany"
                    }, 
                    "name": "1199.93.49004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mannheim", 
                        "country": "Germany"
                    }, 
                    "name": "1199.93.49002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alessandria", 
                        "country": "Italy"
                    }, 
                    "name": "1199.93.39003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergamo", 
                        "country": "Italy"
                    }, 
                    "name": "1199.93.39002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orbassano (TO)", 
                        "country": "Italy"
                    }, 
                    "name": "1199.93.39001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1199.93.44003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1199.93.44004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1199.93.44001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1199.93.44002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wythenshawe", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1199.93.44005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Canada", 
                "Denmark", 
                "France", 
                "Germany", 
                "Italy", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Double Blind, Randomised, Multicentre, Phase II Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Human Research Ethics Committee", 
                "Canada: Health Canada", 
                "Denmark: The Danish Health and Medicines Authority", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: National Institute of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival measured from the time of randomisation to the time of disease progression or death of any cause, whichever occurs earlier", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907100"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival measured from the time of randomisation to the time of death of any cause", 
                "safety_issue": "No", 
                "time_frame": "up to 4 years"
            }, 
            {
                "measure": "Change from baseline in forced vital capacity (pulmonary function)", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}